Comments submitted by industry members about CMS’s TCET notice highlight the need for greater device eligibility and transparency for the pathway.
In comments submitted to the US Center for Medicare and Medicaid Services, industry members asked for greater transparency and eligibility for the office’s Transitional Coverage for Emerging Technologies (TCET) pathway.
In June, CMS put out a notice with a comment period for the TCET pathway and asked for industry members
CMS should…
Expand device eligibility for TCET;
Increase transparency for program acceptances and rejections;
Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.
In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.
Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.
